A multiplex protein panel assay determines disease severity and is prognostic about outcome in COVID-19 patients
Ziyue Wang, Adam Cryar, Oliver Lemke, Daniela Ludwig, Pinkus Tober-Lau, Elisa Theresa Helbig, Daniel Blake, Catherine S Lane, Rebekah L Sayers, Christoph Mueller, Johannes Zeiser, StJohn Townsend, Vadim Demichev, Michael Mülleder, View ORCID ProfileFlorian Kurth, View ORCID ProfileErnestas Sirka, View ORCID ProfileJohannes Hartl, View ORCID ProfileMarkus Ralser
doi: https://doi.org/10.1101/2021.12.03.21267253
Ziyue Wang
1Department of Biochemistry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Am Chariteplatz 1, Berlin, Germany
Adam Cryar
2Inoviv, London, United Kingdom
Oliver Lemke
1Department of Biochemistry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Am Chariteplatz 1, Berlin, Germany
Daniela Ludwig
1Department of Biochemistry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Am Chariteplatz 1, Berlin, Germany
Pinkus Tober-Lau
3Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
Elisa Theresa Helbig
3Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
Daniel Blake
4SCIEX, Macclesfield, United Kingdom
Catherine S Lane
4SCIEX, Macclesfield, United Kingdom
Rebekah L Sayers
4SCIEX, Macclesfield, United Kingdom
Christoph Mueller
5Agilent Technologies Sales & Services GmbH & Co. KG, Waldbronn, Germany
Johannes Zeiser
5Agilent Technologies Sales & Services GmbH & Co. KG, Waldbronn, Germany
StJohn Townsend
1Department of Biochemistry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Am Chariteplatz 1, Berlin, Germany
Vadim Demichev
1Department of Biochemistry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Am Chariteplatz 1, Berlin, Germany
Michael Mülleder
6Core Facility – High-Throughput Mass Spectrometry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Core Facility – High-Throughput Mass Spectrometry, Am Chariteplatz 1, Berlin, Germany
Florian Kurth
3Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
7Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, and Department of Medicine I, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
Ernestas Sirka
2Inoviv, London, United Kingdom
Johannes Hartl
1Department of Biochemistry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Am Chariteplatz 1, Berlin, Germany
Markus Ralser
1Department of Biochemistry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Am Chariteplatz 1, Berlin, Germany
Posted December 05, 2021.
A multiplex protein panel assay determines disease severity and is prognostic about outcome in COVID-19 patients
Ziyue Wang, Adam Cryar, Oliver Lemke, Daniela Ludwig, Pinkus Tober-Lau, Elisa Theresa Helbig, Daniel Blake, Catherine S Lane, Rebekah L Sayers, Christoph Mueller, Johannes Zeiser, StJohn Townsend, Vadim Demichev, Michael Mülleder, Florian Kurth, Ernestas Sirka, Johannes Hartl, Markus Ralser
medRxiv 2021.12.03.21267253; doi: https://doi.org/10.1101/2021.12.03.21267253
A multiplex protein panel assay determines disease severity and is prognostic about outcome in COVID-19 patients
Ziyue Wang, Adam Cryar, Oliver Lemke, Daniela Ludwig, Pinkus Tober-Lau, Elisa Theresa Helbig, Daniel Blake, Catherine S Lane, Rebekah L Sayers, Christoph Mueller, Johannes Zeiser, StJohn Townsend, Vadim Demichev, Michael Mülleder, Florian Kurth, Ernestas Sirka, Johannes Hartl, Markus Ralser
medRxiv 2021.12.03.21267253; doi: https://doi.org/10.1101/2021.12.03.21267253
Subject Area
Subject Areas
- Addiction Medicine (382)
- Allergy and Immunology (699)
- Anesthesia (189)
- Cardiovascular Medicine (2833)
- Dermatology (242)
- Emergency Medicine (427)
- Epidemiology (12534)
- Forensic Medicine (10)
- Gastroenterology (800)
- Genetic and Genomic Medicine (4413)
- Geriatric Medicine (400)
- Health Economics (712)
- Health Informatics (2840)
- Health Policy (1045)
- Hematology (373)
- HIV/AIDS (893)
- Medical Education (412)
- Medical Ethics (114)
- Nephrology (461)
- Neurology (4168)
- Nursing (220)
- Nutrition (615)
- Oncology (2195)
- Ophthalmology (623)
- Orthopedics (254)
- Otolaryngology (317)
- Pain Medicine (265)
- Palliative Medicine (81)
- Pathology (485)
- Pediatrics (1171)
- Primary Care Research (481)
- Public and Global Health (6754)
- Radiology and Imaging (1484)
- Respiratory Medicine (897)
- Rheumatology (430)
- Sports Medicine (368)
- Surgery (471)
- Toxicology (57)
- Transplantation (200)
- Urology (173)